1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Isodiol International Inc.

Isodiol International Inc.

ISOLF
Isodiol International Inc.US flagOther OTC
0.00
USD
- -
- -
4,914.00Market Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
TTM
Revenue per Share
- -
- -
0.01
0.11
0.91
0.58
0.11
Basic EPS, GAAP
- -
-1.1
-5.86
-1.35
-1.72
-3.28
-2.09
Free Cash Flow per Basic Share
- -
-0.71
-1.03
-1.01
-1.46
-0.74
0.34
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-1.66
-6.48
0.15
1.92
0.03
-0.09
Tangible Book Value per Share
- -
-0.62
-0.5
0.6
1.27
0.18
-0.01
Basic Weighted Avg Shares
- -
1
1
3
21
38
49
Sales/Revenue/Turnover
- -
- -
- -
- -
19
22
5
Operating Margin (%)
- -
- -
-14,750.88
-970.05
-119.6
-142.55
-393.78
Depreciation Expense
- -
- -
- -
- -
1
2
- -
Net Income, GAAP
- -
-1
-9
-4
-36
-126
-102
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-51,693.96
-1,204.15
-188.22
-565.95
-1,939.48
Working Capital
- -
- -
-1
1
16
8
1
LT Debt
- -
- -
- -
- -
- -
5
6
Total Equity
- -
- -
-1
2
48
7
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-176.97
-608.04
-626.5

Capital Structure

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
ST Debt
- -
- -
- -
LT Borrowings
5
5
5
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
49
49
49
Market Capitalization
449
116
83

Working Capital

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
Total Current Assets
13
10
7
Cash, Cash Equivalents & STI
4
2
2
Accounts Receivable, Net
2
2
1
Inventories
1
1
3
Total Current Liabilities
8
8
6
Payables & Accruals
6
6
3
ST Debt
- -
- -
- -
Deferred Revenue
2
2
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
2,005.29%
-85.49%
Free Cash Flow
- -
- -
-6.63%
Net Income, GAAP
- -
- -
249.56%
Sales/Revenue/Turnover
- -
- -
16.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
3
5
6
5
19
2019
6
5
9
-2
22
2020
4
2
1
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
-0.38
-0.36
-0.01
- -
-1.72
2019
-0.12
-0.22
-0.55
- -
-3.28
2020
-0.06
-0.07
-0.02
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Marcos Agramont
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
200 Granville Street Vancouver BC Canada V6C 1S4
IPO Date
Nov 20, 2014
Website
isodiol.com
Similar Companies
Hainan Poly Pharm. Co., Ltd (300630.SZ)
Pharmigene, Inc. (7595.TWO)
NutraLife BioSciences, Inc. (NLBS)
AusCann Group Holdings Ltd (AC8.AX)
Vext Science, Inc. (VEXT.CN)
Baijin Life Science Holdings Limited (1466.HK)
Business
Isodiol International Inc. (ISOLF) engages in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions focused on nutritional health benefits derived from CBD. The company offers pharmaceutical-grade, 99%+ pure naturally isolated CBD isolates and raw ingredients for supply to other manufacturers; micro-encapsulated and nanotechnology-enhanced CBD formulations for enhanced bioavailability; consumer products including tinctures, capsules, beverages such as Pot-O-Coffee and Jamaican-Me-Crazy, skincare and personal care items, Iso-Sport wellness products, and Pawceuticals pet CBD lines; as well as custom-labeled CBD solutions for retailers. Founded in 2014 and headquartered in Escondido, California, with prior addresses in Vancouver, British Columbia, Isodiol operates primarily in Canada and the United States, with past expansions into Mexico, Latin America, Asia, and Europe targeting retail, FDM channels, and online markets. Recent developments include a 2020 non-exclusive distribution agreement with SalesBird LLC for U.S. and international retail expansion; strategic partnership with Vitamin Shoppe for FDM channel distribution; nationwide U.S. launch of Pawceuticals pet products; shift toward online sales and restructuring; and announcements of major international expansion with acquisition of industry-leading CBD patents and strategic assets.